ProtoKinetix

ProtoKinetix Accounts Payable

The Accounts Payable of ProtoKinetix (PKTX) as of Nov 19, 2026 is 124,047.00 USD. In the previous year, Accounts Payable was 44.70 USD — a change of 277,410.07% (higher).

Accounts Payable

124,047.00USD

YoY

277,410.07%

Last updated:

Accounts Payable of ProtoKinetix is 2024 124,047.00 USD. Accounts Payable of ProtoKinetix was 2023 44.70 USD. It decreases by 277,410.07% higher compared to the previous year.

The ProtoKinetix Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2017
26,906.00 USD
Jan 1, 2018
78,885.00 USD
Jan 1, 2019
25.52 USD
Jan 1, 2020
44.96 USD
Jan 1, 2021
93.27 USD
Jan 1, 2022
41.53 USD
Jan 1, 2023
44.70 USD
Jan 1, 2024
124,047.00 USD
The ProtoKinetix Accounts Payable history
YEARAccounts PayableYoY
124,047.00USD+277,410.07%
44.70USD+7.63%
41.53USD-55.47%
93.27USD+107.45%
44.96USD+76.18%
25.52USD-99.97%
78,885.00USD+193.19%
26,906.00USD-40.49%
45,214.00USD+0.34%
45,061.00USD-0.53%
45,301.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Accounts Payable of ProtoKinetix is 124,047.00 USD in 2024.

Accounts Payable of ProtoKinetix changed from 44.70 USD to 124,047.00 USD, representing a 277,410.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ProtoKinetix

All Key Metrics — ProtoKinetix